<?xml version='1.0' encoding='utf-8'?>
<document id="28881501"><sentence text="Drug-drug interaction potential in men treated with enzalutamide: Mind the gap."><entity charOffset="52-64" id="DDI-PubMed.28881501.s1.e0" text="enzalutamide" /></sentence><sentence text="Metastatic castration-resistant prostate cancer (mCRPC) patients are generally older patients with several co-morbidities and are therefore at increased risk of complications due to drug-drug interactions (DDIs)" /><sentence text=" We assessed the prevalence of potential DDIs in a cohort of mCRPC patients treated with enzalutamide"><entity charOffset="89-101" id="DDI-PubMed.28881501.s3.e0" text="enzalutamide" /></sentence><sentence text="" /><sentence text="We conducted a retrospective review of pharmacy records to retrieve individual drug histories of mCRPC patients who started enzalutamide therapy in a tertiary care setting"><entity charOffset="124-136" id="DDI-PubMed.28881501.s5.e0" text="enzalutamide" /></sentence><sentence text=" Potential DDIs were analysed using two international drug interaction compendia: Lexicomp® and Micromedex® , and the Dutch drug database" /><sentence text=" Two potential pharmacodynamic DDIs were analysed" /><sentence text="" /><sentence text="A total of 105 records were evaluated for potential DDIs with enzalutamide"><entity charOffset="62-74" id="DDI-PubMed.28881501.s9.e0" text="enzalutamide" /></sentence><sentence text=" Of 205 different co-medications, 56 were flagged by at least one of the three compendia: Lexicomp, Micromedex and the Dutch drug database flagged for potential DDIs in 85%, 54% and 32%, respectively" /><sentence text=" Eighty-five per cent of DDIs were classified as major" /><sentence text=" The median number of co-medications per patient was 11 (range 1-26)" /><sentence text=" The median (range) number of interactions per patient was 4 (0-10), 1 (0-5) and 0 (0-2) for Lexicomp, Micromedex and the Dutch drug database, respectively" /><sentence text=" In 23% and 45% of all patients, a potential DDI was found with PPIs and CNS depressants, respectively" /><sentence text="" /><sentence text="A high prevalence of potential DDIs was found" /><sentence text=" The inclusion and grading of potential DDIs was highly variable between the three drug interaction compendia" /><sentence text=" Physicians, nurses and pharmacists should be aware of this potential problem, which might require intensive monitoring or alternative treatment strategies to prevent suboptimal treatment of the co-morbidities in patients treated with enzalutamide"><entity charOffset="235-247" id="DDI-PubMed.28881501.s18.e0" text="enzalutamide" /></sentence><sentence text="" /></document>